Forecast horizon — calibration-scored at resolution.
By 2028, at least two additional subretinal gene therapies (beyond LUXTURNA) will be FDA-approved for monogenic retinal dystrophies.
TL;DR · AI-generated
Voretigene neparvovec gene replacement improved functional vision in RPE65-mediated inherited retinal dystrophy previously medically untreatable.
Your probability this resolves TRUE
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
2 events · 1 snapshot
posterior drift
71% → 71% (0pp · 1 point)
Registry data
Apr 18, 2026
Peer-reviewed paper
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65 -mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial
Stephen Russell et al. · The Lancet · 2017
· openalex W2736065260 · s2 e00fcd8a
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.1769
The LUXTURNA (voretigene) trial's stated primary conclusion — Subretinal AAV2-hRPE65 gene therapy improves functional vision in biallelic RPE65-associated inherited retinal dystrophy. — replicates in independent cohorts.
0.1886
Recent follow-up analyses of LUXTURNA (voretigene) are confirming the original effect size in real-world data.
0.1974
By 2028, at least two sickle cell gene-therapy products will compete head-to-head on real-world VOC-free survival and cost-effectiveness.
0.2164
By 2028, universal newborn SMA screening + early nusinersen (or onasemnogene/risdiplam) will be standard across all US states and most EU countries.
0.2410
By 2028, one-time AAV gene therapy for severe hemophilia B will show ≥5-year FIX expression durability in >70% of treated patients.
0.2526
By 2028, exa-cel or a comparable ex vivo gene-edited therapy will have treated >500 SCD patients globally with a durable VOC-free rate >90% at 3 years.